Date Release
December 10 Lundbeck Names Sean Nolan as New CEO of its Lundbeck Inc. U.S. Subsidiary
October 09 Lundbeck Honored with the Marjorie Guthrie Leadership Award for Ongoing Commitment to the Huntington’s Disease Community
September 25 National Association of Neonatal Nurses and Lundbeck Inc. Announce Recipients of Lundbeck Neonatal Nursing Career Path Scholarships
September 21 Sabril® Now Available in U.S. for Patients with Two Difficult-to-Treat Epilepsies
August 31 Lundbeck Inc. Recognized with Award of Excellence in Corporate Achievement for Its Commitment to Huntington’s Disease Community
August 21 Lundbeck Inc. Announces FDA Marketing Approval for Sabril
July 07 Lundbeck Increases its Share of Xenazine® and Strengthens the U.S. Profitability - Transaction Immediately Accretive
June 25 Lundbeck Receives Complete Response Letter on Serdolect® for the Treatment of Schizophrenia
May 15 Lundbeck provides update on NDA for Serdolect® for the treatment of schizophrenia
April 07 FDA Advisory Committee provides opinion on Serdolect® for the treatment of schizophrenia
March 19 Lundbeck's acquisition of Ovation Pharmaceuticals cleared by US Federal Trade Commission
February 26 Ovation Pharmaceuticals Receives Frost & Sullivan's 2009 Entrepreneurial Company of the Year Award
February 25 Ovation Pharmaceuticals Proudly Supports National Rare Disease Day
February 09 Lundbeck to acquire US-based Ovation Pharmaceuticals, Inc. a specialty pharmaceutical company focusing on central nervous system disorders (CNS)
January 08 FDA Advisory Committee Unanimously Recommends Sabril (vigabatrin) for the Treatment of Two Catastrophic Epilepsies
January 07 FDA Advisory Committee Recommends Approval of Sabril (vigabatrin) for the Treatment of Refractory Complex Partial Seizures
You have chosen to visit another Lundbeck website or a third-party website, which is provided as a service to you. Lundbeck does not control content on third-party websites and cannot make representations concerning the accuracy of information on every website you visit. Lundbeck is not responsible for the privacy policy of any third-party website. We encourage you to read the privacy policy of every website you visit. Click OK to continue or Cancel to return to Lundbeck.